Today, the smart healthcare company, MiiS (ticker: 6796), announces that it has signed an exclusive distribution agreement with Clairvo Technologies, a subsidiary which is responsible for digital healthcare businesses in Marubeni Group. According to the agreement, Clairvo will sell and market MiiS’ eye fundus camera with edge computing AI-based software(*1) in Japan. This is a major milestone for MiiS’ product to penetrate the Japanese market and endorse Company’s commitment to explore the new markets.
Marubeni represents a large-scale, comprehensive trading company in Japan that manages products and provides value-added services across the board. Its subsidiary, Clairvo Technologies, has been developing most advanced technologies and excellent products to the healthcare industry in Japan and Asian countries. The collaboration between MiiS and Clairvo has been moving on in great progress for two years, and recently the AI-DR software has obtained approval by a registered certification body under Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices in Japan and received a Class II medical device certificate, making a significant progress for strategic partnership. Clairvo plans to sell the products to medical and long-term nursing care institutions.
In addition to the Japanese market, MiiS also aims to cultivate the Southeast Asian market. Several products are currently under registration for local licenses. MiiS is confidently hoping that through market expanding the market expansion, MiiS will bring advanced technology and products to every corner of the world.
About Medimaging Integrated Solution Inc. and AI-DR software
Medimaging Integrated Solution Inc. (MiiS)(ticker: 6796) is a global leading provider of smart healthcare solutions, focusing on three main markets: telemedicine (digital hand-held diagnostic scopes), digital medicine (AI medical image-assisted diagnosis software), and minimally invasive diagnosis and treatment (disposable endoscopes). MiiS is dedicated to developing innovative smart medical devices by combining core technologies of optics design for digital medical image with AI medical image-assisted diagnosis software, and providing innovative medical solutions. MiiS is based in Hsinchu, Taiwan and selling products either under its own brand, horus SCOPE, or CDMO service, reaching over 60 countries globally. For more information, please visit MiiS website: https://www.miis.com.tw.
(*1) This software is called AI-DR (Diabetic Retinopathy), which is the very first innovation of analyzing fundus images, providing real-time classification, staging, and symptom location of diabetic retinopathy developed in Taiwan. With a sensitivity of over 98% and a specificity of over 96%, its performance surpasses other products in the market and effectively assists doctors in understanding the severity of the condition and the location of retinal damage. It also helps non-ophthalmologists decide whether a patient needs to be referred to an ophthalmologist. Whether applied in well-equipped medical facilities or remote clinics, it enhances the early screening capability of diabetic retinopathy, improves the efficient allocation of medical resources, and assists in monitoring the control of diabetic retinopathy patients. In Japan, this software has not been approved to diagnose diabetic retinopathy.
▶ Marubeni Group press release > https://www.marubeni.com/jp/news/2023/group/00009.html
▶ Clairvo Technologies Inc. press release > https://www.clairvotech.com/news/Miis_release_0210.html
